STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. “We are now approaching a period during which several portfolio companies will conclude their clinical studies, yielding exciting data readouts”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the third quarter Karolinska Development announced an update from Organon on the development of ...